Tango Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Tango Therapeutics, Inc. (TNGX) holds an ST Score of 46.1 out of 100 (C+), with its strongest factor being Profitability (A-) and its weakest Sentiment (F). Analysts rate TNGX Buy across 13 ratings with a $45.91 average price target (+1.1% vs the current $21.75).
- Strongest
- ProfitabilityA-
- Weakest
- SentimentF
All factor grades
- ProfitabilityA-
- ForecastA-
- Financial StrengthB+
- ValuationB
- MomentumB-
- GrowthF
- SentimentF
- Piotroski2/9
Contact
TNGX stock: frequently asked questions
What is TNGX's ST Score?
Tango Therapeutics, Inc. (TNGX) has an ST Score of 46.1 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is TNGX a buy, sell, or hold?
Wall Street's consensus rating on TNGX is Buy based on 13 analyst ratings. Our own ST Score grades it C+ (46.1/100). This is data, not investment advice — always do your own research.
What is TNGX's valuation grade?
Tango Therapeutics, Inc. (TNGX) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is TNGX's growth grade?
Tango Therapeutics, Inc. (TNGX) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is TNGX's profitability grade?
Tango Therapeutics, Inc. (TNGX) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is TNGX's financial strength grade?
Tango Therapeutics, Inc. (TNGX) earns a financial strength grade of B+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for TNGX?
The average analyst price target for Tango Therapeutics, Inc. (TNGX) is $45.91 from 13 analysts, which is +1.1% versus the recent price of $21.75.
What is TNGX's Piotroski score?
Tango Therapeutics, Inc. (TNGX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.